References
- Hendrick AM, Gibson MV, Kulshreshtha A. Diabetic retinopathy. Prim Care. 2015;42(3):451–464.
- Hammes HP. Diabetic retinopathy: hyperglycaemia, oxidative stress and beyond. Diabetologia. 2018;61(1):29–38.
- Li C, Miao X, Li F, et al. Oxidative stress-related mechanisms and antioxidant therapy in diabetic retinopathy. Oxid Med Cell Longev. 2017;2017:9702820.
- Lechner J, O'Leary OE, Stitt AW. The pathology associated with diabetic retinopathy. Vision Res. 2017;139:7–14.
- Bellezza I, Giambanco I, Minelli A, et al. Nrf2-keap1 signaling in oxidative and reductive stress. Biochim Biophys Acta Mol Cell Res. 2018;1865(5):721–733.
- Tonelli C, Chio IIC, Tuveson DA. Transcriptional regulation by nrf2. Antioxid Redox Signal. 2018;29(17):1727–1745.
- Kowluru RA, Mishra M. Epigenetic regulation of redox signaling in diabetic retinopathy: role of nrf2. Free Radic Biol Med. 2017;103:155–164.
- Deliyanti D, Alrashdi SF, Tan SM, et al. Nrf2 activation is a potential therapeutic approach to attenuate diabetic retinopathy. Invest Ophthalmol Vis Sci. 2018;59(2):815–825.
- Li Y, Wright GL, Peterson JM. C1q/TNF-related protein 3 (ctrp3) function and regulation. Compr Physiol. 2017;7(3):863–878.
- Elsaid HH, Elgohary MN, Elshabrawy AM. Complement c1q tumor necrosis factor-related protein 3 a novel adipokine, protect against diabetes mellitus in young adult Egyptians. Diabetes Metab Syndr. 2019;13(1):434–438.
- Yan Z, Zhao J, Gan L, et al. Ctrp3 is a novel biomarker for diabetic retinopathy and inhibits hghl-induced vcam-1 expression in an ampk-dependent manner. PLoS ONE. 2017;12(6):e0178253.
- Calderon GD, Juarez OH, Hernandez GE, et al. Oxidative stress and diabetic retinopathy: development and treatment. Eye (Lond). 2017;31(8):1122–1130.
- Dehdashtian E, Mehrzadi S, Yousefi B, et al. Diabetic retinopathy pathogenesis and the ameliorating effects of melatonin; involvement of autophagy, inflammation and oxidative stress. Life Sci. 2018;193:20–33.
- Moradi N, Fadaei R, Khamseh ME, et al. Serum levels of ctrp3 in diabetic nephropathy and its relationship with insulin resistance and kidney function. PLoS ONE. 2019;14(4):e0215617.
- Hu TY, Li LM, Pan YZ. Ctrp3 inhibits high glucose-induced human glomerular mesangial cell dysfunction. J Cell Biochem. 2019;120(4):5729–5736.
- Ma ZG, Yuan YP, Xu SC, et al. Ctrp3 attenuates cardiac dysfunction, inflammation, oxidative stress and cell death in diabetic cardiomyopathy in rats. Diabetologia. 2017;430(6):1–12.
- Deshmukh P, Unni S, Krishnappa G, et al. The keap1–nrf2 pathway: promising therapeutic target to counteract ros-mediated damage in cancers and neurodegenerative diseases. Biophys Rev. 2017;9(1):41–56.
- Taguchi K, Motohashi H, Yamamoto M. Molecular mechanisms of the keap1-nrf2 pathway in stress response and cancer evolution. Genes Cells. 2011;16(2):123–140.
- Sajadimajd S, Khazaei M. Oxidative stress and cancer: the role of nrf2. Curr Cancer Drug Targets. 2018;18(6):538–557.
- Nabavi SF, Barber AJ, Spagnuolo C, et al. Nrf2 as molecular target for polyphenols: a novel therapeutic strategy in diabetic retinopathy. Crit Rev Clin Lab Sci. 2016;53(5):293–312.
- Xu Z, Wei Y, Gong J, et al. Nrf2 plays a protective role in diabetic retinopathy in mice. Diabetologia. 2014;57(1):204–213.